title: New and Investigational Agents for Irritable Bowel Syndrome.
abstract: Irritable bowel syndrome (IBS) affects about 15 % of the US population and results in significant morbidity and health care costs. There remains a significant unmet need for effective treatments particularly for the pain component of IBS and other functional gastrointestinal disorders (FGIDs). Progress made in our understanding of pathophysiological mechanisms such as the role of altered bile acid metabolism, neurohormonal regulation, immune dysfunction, the epithelial barrier and secretory properties of the gut has led to advancements in therapeutic armamentarium for IBS. This review discusses the new drugs for constipation and diarrhea-predominant IBS subtypes that have been tested or have been under investigation over the last 3-4 years. Overall, there is a promising pipeline of investigational drugs for the future treatment of IBS and related FGIDs.
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. wadhwa.akhilesh@mayo.edu.
authors.forename: Akhilesh
authors.initials: A
authors.lastname: Wadhwa
authors.affiliation: Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. camilleri.michael@mayo.edu.
authors.forename: Michael
authors.initials: M
authors.lastname: Camilleri
authors.affiliation: Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. grover.madhusudan@mayo.edu.
authors.forename: Madhusudan
authors.initials: M
authors.lastname: Grover
mesh_terms: D003248:Constipation / Q000188:drug therapy; D003967:Diarrhea / Q000188:drug therapy; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D017461:Receptors, Atrial Natriuretic Factor / Q000819:agonists; D058828:Serotonin 5-HT4 Receptor Agonists / Q000627:therapeutic use
chemical_list: D005765:Gastrointestinal Agents; D058828:Serotonin 5-HT4 Receptor Agonists; D017461:Receptors, Atrial Natriuretic Factor; C073616:atrial natriuretic factor receptor C
keywords: Constipation; Diarrhea; Drugs; Functional gastrointestinal disorders; Pain; Treatment